Roselabs Finance Limited has officially announced a board meeting scheduled for April 16, 2026, to deliberate and approve the company's audited financial results for the fourth quarter and full financial year ended March 31, 2026. The announcement was communicated to BSE Limited on April 13, 2026, in accordance with regulatory requirements.

Board Meeting Details

The meeting has been convened under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The board will focus on reviewing and approving the audited financial results for both Q4FY26 and the complete FY26 period.

Trading Window Restrictions

Roselabs Finance Limited has implemented trading window restrictions as part of its insider trading prevention measures. The trading window for dealing in company shares has been closed for all designated persons with effect from April 1, 2026. This closure will remain in effect until 48 hours after the declaration of financial results by the company.

The trading window closure was previously communicated through the company's letter dated March 23, 2026, and aligns with the company's Code of Conduct for Prevention of Insider Trading.

Regulatory Compliance

The board meeting intimation has been filed in compliance with Regulation 29 of the SEBI Listing Regulations. Company Secretary and Compliance Officer Gunjan Taunk signed the official communication, which was digitally authenticated on April 13, 2026. The intimation has also been uploaded on the company's official website at www.roselabsfinancelimited.in to ensure transparent disclosure to all stakeholders.

The company continues to maintain strict adherence to regulatory requirements and corporate governance standards in its financial reporting and disclosure processes.

Roselabs Finance Limited has announced its unaudited financial results for the quarter ended December 31, 2025, showing improved performance with a narrowed net loss despite operational challenges. The Board of Directors approved these results at a meeting held on January 20, 2026, with statutory auditors MSKA & Associates LLP providing an unmodified opinion on the financial statements.

Financial Performance Overview

The company's financial performance for Q3FY26 demonstrated significant improvement compared to the corresponding quarter of the previous year:

Nine-Month Performance Analysis

For the nine months ended December 31, 2025, Roselabs Finance showed considerable improvement in its financial position:

Expense Structure and Cost Management

The company's expense breakdown for Q3FY26 reveals the operational structure of its real estate development business. Cost of projects constituted the largest expense component at ₹119.55 crores, directly correlating with the revenue generation. Employee benefits expenses remained controlled at ₹1.25 crores, while other expenses totaled ₹3.62 crores, showing improved cost management compared to ₹9.89 crores in Q3FY25.

Corporate Developments

Roselabs Finance operates exclusively in the real estate development segment with operations confined to India. The company has no subsidiaries, joint ventures, or associate companies, eliminating the need for consolidated financial statements. A significant corporate development involves the proposed merger with Lodha Developers Limited (formerly Macrotech Developers Limited), which received BSE approval on December 30, 2025. The company is currently in the process of filing the merger application with the NCLT Mumbai Bench.

Capital Structure and Shareholding

The company maintains a stable capital structure with paid-up equity share capital of ₹1,000.00 crores, consisting of shares with a face value of ₹10 each. This capital base has remained unchanged across all reported periods, providing stability for the company's operations and strategic initiatives.

Regulatory Compliance and Audit Opinion

The financial results were prepared in accordance with Indian Accounting Standard 34 for Interim Financial Reporting and comply with SEBI Listing Regulations. The statutory auditors conducted their review in accordance with Standard on Review Engagement (SRE) 2410 and expressed an unmodified conclusion, indicating no material concerns with the financial statements' preparation and presentation.